Evidence map›Paper›PMID 38819662›Full record

Trial reportEuropean child & adolescent psychiatry2024

Problems most concerning to parents of children with ADHD and emotional dysregulation in a randomized controlled trial of multinutrients: MADDY secondary analysis.

Gabriella Tost, Priya Srikanth, Alisha Bruton, Irene E Hatsu, Brenda My Leung, Hayleigh K Ast, Leanna P Eiterman, Lisa M Robinette, Craig Williams, Barbara Gracious and 2 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in European child & adolescent psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Annual Research Review: Micronutrients and their role in the treatment of paediatric mental illness.Journal of child psychology and psychiatry, and allied disciplines · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gabriella TostCenter for Mental Health Innovation, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, DC7P, Portland, Oregon, 97239, United States.
Priya SrikanthOHSU-Portland State University School of Public Health, Portland, Oregon, United States.
Alisha BrutonCenter for Mental Health Innovation, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, DC7P, Portland, Oregon, 97239, United States.
Irene E HatsuCenter for Mental Health Innovation, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, DC7P, Portland, Oregon, 97239, United States.
Brenda My LeungUniversity of Lethbridge, Alberta, Canada.
Hayleigh K AstCenter for Mental Health Innovation, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, DC7P, Portland, Oregon, 97239, United States.
Leanna P EitermanThe Ohio State University, Columbus, Ohio, United States.
Lisa M RobinetteThe Ohio State University, Columbus, Ohio, United States.
Craig WilliamsThe Ohio State University, Columbus, Ohio, United States.
Barbara GraciousThe Ohio State University, Columbus, Ohio, United States.
L Eugene ArnoldThe Ohio State University, Columbus, Ohio, United States.
Jeanette M JohnstoneNational University of Natural Medicine, Helfgott Research Institute, Portland, Oregon, United States. jojeanet@ohsu.edu.

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
Oregon Clinical and Translational Research InstituteUL1TR000128 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLISON, DAVID H · 2012 to 2015
$28.7M
The Ohio State University Center for Clinical and Translational Science (UL1)UL1TR000090 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2012 to 2013
$7.9M
CAM Research Training in Neuroscience &StressT32AT002688 · NCCIH · OREGON HEALTH & SCIENCE UNIVERSITY · PI OKEN, BARRY S, SOUMYANATH, AMALA · 2005 to 2025
$7.2M
Double-Blind Randomized Clinical Trial of EEG Neurofeedback for ADHDR01MH100144 · NIMH · OHIO STATE UNIVERSITY · PI ARNOLD, L EUGENE · 2014 to 2018
$3.5M
Optimizing Research Methodology in a Multinutrient Study of Racially and Ethnically Diverse Children with ADHD and Emotional DysregulationK23AT012068 · NCCIH · OREGON HEALTH & SCIENCE UNIVERSITY · PI JOHNSTONE, JEANETTE M · 2022 to 2025
$700k
National Center for Advancing Translational Sciences,United States 8UL1TR000090-05National Center for Advancing Translational Sciences,United States UL1TR002369NCATS NIH HHS UL1 TR000090NCATS NIH HHS UL1 TR000128NCATS NIH HHS UL1TR000128NCATS NIH HHS UL1 TR002369NCCIH NIH HHS K23 AT012068NCCIH NIH HHS T32 AT002688NCCIH NIH HHS T32AT002688NIMH NIH HHS R01 MH100144
6 · The paper itself

Abstract

objectiveWith dual focus on structured, objective quantification of parent observations of child's behavior and identifying behaviors most amenable to change, this report examines Parent Target Problems (PTP) as a secondary outcome in a randomized clinical trial (RCT) of children with attention-deficit/ hyperactivity disorder (ADHD) in which one primary outcome, Clinical Global Impression-Improvement, showed a significant advantage of multinutrients over placebo and the other, Likert-type parent ratings, showed significant improvement in both groups, without significant difference between them.

methodIn a multisite 8-week RCT of broad-spectrum micronutrients ("multinutrients"), parents of children ages 6-12 (N = 126, 73% male, 88% white) with ADHD and emotional dysregulation nominated their child's most concerning problem(s) at baseline and quantified them by frequency, duration, impairment, and consequences. At subsequent visits, parents re-quantified the problem(s). Blinded child psychiatrists independently reviewed the PTPs and rated change at two timepoints compared to baseline. PTPs were grouped into 9 categories. Mean ratings were compared between active and placebo groups and explored by category.

resultsBy week 8, a significant separation favored multinutrients: 38% of the multinutrient group were "definitely improved" or better, compared to 25% of the placebo group, and ratings of "no change" or "worse" occurred in 35% with placebo versus 23% with multinutrients (p = 0.04). Inattention (72.2%) and emotional dysregulation (69.1%) were the most frequently reported PTP categories. Inattention and internalizing symptoms improved more with multinutrients than placebo (p = 0.01, d = 0.55; p = 0.03, d = 0.80, respectively). The multinutrient advantage was not significant for 7 other symptoms, including hyperactivity/impulsivity, aggression, autistic symptoms, or emotional dysregulation/irritable oppositionality.

conclusionsThis secondary analysis found that the multinutrients, compared to placebo, were associated with improvements in parental concerns overall, and in two domains specifically: inattention and internalizing symptoms (anxiety/depression), but not in seven domains: hyperactivity/impulsivity, aggression, autistic symptoms or physiological symptoms, peer relationships or emotional dysregulation/irritable oppositionality.

Indexed as

Attention Deficit Disorder with HyperactivityParentsChildEmotional RegulationFemaleHumansMaleMicronutrientsMicronutrientsADHDInattentionInternalizing symptomsMicronutrientsMultinutrientsParent reportsRCT

Identifiers

PMID38819662
PMCPMC11607173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.